{
    "nctId": "NCT00055861",
    "briefTitle": "Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer",
    "officialTitle": "PHASE 2 STUDY OF BEVACIZUMAB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH ADVANCED BREAST CANCER",
    "overallStatus": "COMPLETED",
    "conditions": "Recurrent Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 27,
    "primaryOutcomeMeasure": "Response rate according to Response Evaluation Criteria in Solid Tumors (RECIST)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed breast cancer\n\n  * Local-regional recurrences or metastatic disease\n* At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan\n* No history or evidence of CNS disease (e.g., primary brain tumor or any brain metastases)\n* Hormone receptor status:\n\n  * Not specified\n* Female\n* Performance status - ECOG 0-2\n* Performance status - Karnofsky 60-100%\n* More than 3 months\n* WBC at least 3,000/mm\\^3\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* No bleeding diathesis or coagulopathy\n* Bilirubin normal\n* AST/ALT no greater than 2.5 times upper limit of normal\n* INR less than 1.5 (patients receiving warfarin)\n* Creatinine normal\n* Creatinine clearance at least 60 mL/min\n* No baseline proteinuria\n\n  * Patients with proteinuria of 1+ or greater at baseline are allowed provided 24-hour urinary protein is less than 500 mg\n* No symptomatic congestive heart failure\n* No cardiac arrhythmia\n* No uncontrolled hypertension\n* No history of stroke\n* No clinically significant peripheral artery disease\n* No arterial thromboembolic event within the past 6 months, including any of the following:\n\n  * Transient ischemic attack\n  * Cerebrovascular accident\n  * Unstable angina\n  * Myocardial infarction\n* HIV negative\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No seizures not controlled with standard medical therapy\n* No prior allergic reactions attributed to compounds of similar chemical or biological composition to study agents\n* No psychiatric illness or social situation that would preclude study compliance\n* No ongoing or active infection\n* No other concurrent uncontrolled illness\n* No non-healing wounds\n* No significant traumatic injury within the past 28 days\n* Prior adjuvant chemotherapy allowed (up to 1 regimen for metastatic disease)\n\n  * More than 6 months since prior taxane-containing adjuvant chemotherapy\n* More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered\n* More than 3 weeks since prior radiotherapy\n* More than 28 days since prior major surgery or open biopsy\n* More than 7 days since prior fine needle aspirations other than in the breast\n* More than 7 days since prior placement of a vascular access device\n* No concurrent major surgical procedure\n* No concurrent or recent full-dose oral or parenteral anticoagulants or thrombolytic agents (except as required to maintain patency of preexisting, permanent indwelling IV catheters)\n* No other concurrent investigational agents\n* No concurrent chronic daily aspirin (more than 325 mg/day) or nonsteroidal anti-inflammatory medications (known to inhibit platelet function at doses used to treat chronic inflammatory diseases)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}